First look at evaluation of serum angiopoietin-like 4 levels in bladder cancer: A pilot study.

Bladder cancer continues to represent a considerable global health burden, characterized by increasing incidence and mortality rates. Despite its prevalence as one of the most common urological malignancies, diagnosis remains challenging due to the scarcity of dependable, non-invasive biomarkers. Consequently, the imperative to identify novel biomarkers for effective diagnosis becomes evident. This study included 101 hospital patients, whose were stratified according to biopsy-confirmed histopathological diagnosis into the bladder cancer group (n=69) and the non-cancer group (n=32). Serum angiopoietin-like 4 (ANGPTL4) concentrations were quantified using an enzyme-linked immunosorbent assay (ELISA). Significantly lower serum ANGPTL4 levels (approximately 28% lower) were observed in the bladder cancer cohort compared to the non-cancer group (p=0.043). The optimal cut-off value was 16.95 ng/ml, yielding a sensitivity of 74% and a specificity of 53%. The Youden Index was established at 0.2704. The presented findings indicate that ANGPTL4 poorly differentiates patients with bladder cancer from non-cancer patients.